-
1.发明申请METHODS, COMPOSITIONS, AND KITS FOR TREATING SHIGA TOXIN ASSOCIATED CONDITIONS 审中-公开用于治疗SHIGA毒素相关条件的方法，组合物和试剂盒公开(公告)号：US20120195891A1
公开(公告)日：2012-08-02
申请号：US13412735
申请日：2012-03-06
申请人： Marc Riviere , Claire Thuning-Roberson , Mariam Mehran , Alison O'Brien , Angela Melton-Celsa , Janique Sam-Pan
发明人： Marc Riviere , Claire Thuning-Roberson , Mariam Mehran , Alison O'Brien , Angela Melton-Celsa , Janique Sam-Pan
CPC分类号： C07K16/1232 , A61K2039/505 , A61K2039/507 , C07K14/245 , C07K2317/24
摘要： The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies.
摘要翻译： 本发明的特征在于用嵌合抗滋贺毒素1（cαStx1）和抗滋贺毒素2（cαStx2）抗体治疗具有志贺毒素相关疾病的受试者的方法，组合物和试剂盒。
-
2.发明申请METHODS, COMPOSITIONS, AND KITS FOR TREATING SHIGA TOXIN ASSOCIATED CONDITIONS 审中-公开用于治疗SHIGA毒素相关条件的方法，组合物和试剂盒公开(公告)号：US20090258010A1
公开(公告)日：2009-10-15
申请号：US12302748
申请日：2007-05-31
申请人： Marc Riviere , Claire Thuning-Roberson , Mariam Mehran , Alison O'Brien , Angela Melton-Celsa , Janique Sam-Pan
发明人： Marc Riviere , Claire Thuning-Roberson , Mariam Mehran , Alison O'Brien , Angela Melton-Celsa , Janique Sam-Pan
IPC分类号： A61K39/395
CPC分类号： C07K16/1232 , A61K2039/505 , A61K2039/507 , C07K2317/24
摘要： The invention features methods, compositions, and kits for treating a subject having a Shiga toxin associated disease with chimeric anti-Shiga Toxin 1 (cαStx1) and anti-Shiga Toxin 2 (cαStx2) antibodies.
摘要翻译： 本发明的特征在于用嵌合抗滋贺毒素1（calphaStx1）和抗滋贺毒素2（calphaStx2）抗体治疗具有志贺毒素相关疾病的受试者的方法，组合物和试剂盒。
-
公开(公告)号：US08969529B2
公开(公告)日：2015-03-03
申请号：US13142556
申请日：2010-01-21
CPC分类号： A61K39/0283 , A61K38/00 , A61K39/0258 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/25 , C07K16/1232 , C07K2317/34 , Y02A50/473
摘要： The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.
摘要翻译： 本发明基于11 E1O抗体的Stx2蛋白中的表位的发现。 本发明的特征在于包含非全长Stx2多肽的组合物，其包括11E1O单克隆抗体表位。 本发明还具有产生对Stx2蛋白的11E1O表位特异的抗Stx2抗体的方法。 另外，本发明的特征在于用包含11个E1O的多肽治疗具有或有发展志贺毒素相关疾病（例如，溶血性尿毒症综合征和与大肠杆菌和痢疾杆菌感染相关的疾病）的受试者的方法 表位或使用本发明的方法开发的抗Stx2抗体。 此外，本发明的特征在于使用使用本发明的方法开发的抗体检测样品中的Stx2。
-
4.发明申请Humanized monoclonal antibodies that protect against shiga toxin induced disease 审中-公开防止志贺毒素诱发疾病的人源化单克隆抗体公开(公告)号：US20070003560A1
公开(公告)日：2007-01-04
申请号：US11471369
申请日：2006-06-20
CPC分类号： C07K16/1232 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.
摘要翻译： 本发明描述了生物学和免疫学活性的人源化单克隆抗体与志贺毒素（一种与HC相关的毒素）和潜在的危及生命的后遗症HUS由病原菌菌株传播的制备和应用。 本发明描述了这些人源化抗体如何用于治疗或预防志贺毒素诱导的疾病。 本发明的一个方面是结合志贺毒素的人源化单克隆抗体，其中恒定区是IgG1-κ，可变区是起源的鼠。 本发明的另一方面是用表达本发明的人源化单克隆抗体的载体转化的表达载体和宿主细胞。
-
公开(公告)号：US20070292426A1
公开(公告)日：2007-12-20
申请号：US11788546
申请日：2007-04-20
IPC分类号： A61K38/00 , A61P43/00 , C07H21/04 , C07K14/00 , C07K16/00 , C12N15/00 , C12N5/00 , C12N5/02 , C12P21/04 , C12P21/08 , G01N33/00 , G01N33/53
CPC分类号： A61K39/3955 , A61K2039/505 , C07K14/245 , C07K16/1228 , C07K16/1232 , C07K16/18 , C07K2317/76 , G01N33/53
摘要： The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 13C4 epitope or with an anti-Stx1 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx1 in a sample using the antibodies developed using the methods of the invention.
摘要翻译： 本发明基于用于13C4抗体的Stx1蛋白中的表位的发现。 本发明的特征是非全长Stx1多肽，其包括13C4单克隆抗体表位的表位。 本发明还具有产生对Stx1蛋白的13C4表位特异的抗Stx1抗体的方法。 另外，本发明的特征在于具有包含13C4表位的多肽或具有发展志贺毒素相关疾病（例如，溶血性尿毒症综合征和与大肠杆菌和痢疾杆菌感染相关的疾病）的受试者的方法。 或使用本发明的方法开发的抗Stx1抗体。 此外，本发明的特征在于使用使用本发明的方法开发的抗体检测样品中的Stx1。
-
公开(公告)号：US08293245B2
公开(公告)日：2012-10-23
申请号：US11788546
申请日：2007-04-20
IPC分类号： A61K39/00
CPC分类号： A61K39/3955 , A61K2039/505 , C07K14/245 , C07K16/1228 , C07K16/1232 , C07K16/18 , C07K2317/76 , G01N33/53
摘要： The invention is based on the discovery of the epitope in the Stx1 protein for the 13C4 antibody. The invention features non-full length Stx1 polypeptides that include the epitope for the 13C4 monoclonal antibody epitope. The invention also features methods of producing anti-Stx1 antibodies specific for the 13C4 epitope of the Stx1 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 13C4 epitope or with an anti-Stx1 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx1 in a sample using the antibodies developed using the methods of the invention.
摘要翻译： 本发明基于用于13C4抗体的Stx1蛋白中的表位的发现。 本发明的特征是非全长Stx1多肽，其包括13C4单克隆抗体表位的表位。 本发明还具有产生对Stx1蛋白的13C4表位特异的抗Stx1抗体的方法。 另外，本发明的特征在于具有包含13C4表位的多肽或具有发展志贺毒素相关疾病（例如，溶血性尿毒症综合征和与大肠杆菌和痢疾杆菌感染相关的疾病）的受试者的方法。 或使用本发明的方法开发的抗Stx1抗体。 此外，本发明的特征在于使用使用本发明的方法开发的抗体检测样品中的Stx1。
-
公开(公告)号：US20110318357A1
公开(公告)日：2011-12-29
申请号：US13142556
申请日：2010-01-21
IPC分类号： A61K39/00 , C12N15/11 , C12N15/70 , A61K38/02 , C07K16/12 , C12N1/21 , A61P31/00 , A61P37/04 , C12P21/00 , C12N5/16 , G01N33/566 , C07K19/00 , A61K39/40
CPC分类号： A61K39/0283 , A61K38/00 , A61K39/0258 , A61K2039/505 , C07K7/06 , C07K7/08 , C07K14/25 , C07K16/1232 , C07K2317/34 , Y02A50/473
摘要： The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.
摘要翻译： 本发明基于11 E1O抗体的Stx2蛋白中的表位的发现。 本发明的特征在于包含非全长Stx2多肽的组合物，其包括11E1O单克隆抗体表位。 本发明还具有产生对Stx2蛋白的11E1O表位特异的抗Stx2抗体的方法。 另外，本发明的特征在于用包含11个E1O的多肽治疗具有或有发展志贺毒素相关疾病（例如，溶血性尿毒症综合征和与大肠杆菌和痢疾杆菌感染相关的疾病）的受试者的方法 表位或使用本发明的方法开发的抗Stx2抗体。 此外，本发明的特征在于使用使用本发明的方法开发的抗体检测样品中的Stx2。
-
公开(公告)号：US20070160607A1
公开(公告)日：2007-07-12
申请号：US11471420
申请日：2006-06-20
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06 , C07K16/18
CPC分类号： C07K16/1232 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.
-
公开(公告)号：US20100166753A1
公开(公告)日：2010-07-01
申请号：US12647845
申请日：2009-12-28
CPC分类号： C07K16/1232 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.
-
10.发明申请HUMANIZED MONOCLONAL ANTIBODIES THAT PROTECT AGAINST SHIGA TOXIN INDUCED DISEASE 审中-公开保护针对SHIGA诱导性疾病的人类单克隆抗体公开(公告)号：US20100189715A1
公开(公告)日：2010-07-29
申请号：US12536940
申请日：2009-08-06
IPC分类号： A61K39/395 , A61P31/04
CPC分类号： C07K16/1232 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.
摘要翻译： 本发明描述了生物学和免疫学活性的人源化单克隆抗体与志贺毒素（一种与HC相关的毒素）和潜在的危及生命的后遗症HUS由病原菌菌株传播的制备和应用。 本发明描述了这些人源化抗体如何用于治疗或预防志贺毒素诱导的疾病。 本发明的一个方面是结合志贺毒素的人源化单克隆抗体，其中恒定区是IgG1-κ，可变区是起源的鼠。 本发明的另一方面是用表达本发明的人源化单克隆抗体的载体转化的表达载体和宿主细胞。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.036 秒)
